Skip to main content
Erschienen in: Clinical Autonomic Research 1/2024

02.03.2024 | Research Article

Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study

verfasst von: Timi Earl, Amani Jridi, Perla C. Thulin, Meghan Zorn, Kathleen E. McKee, Kristin Mitrovich, Paolo Moretti, Jumana Alshaikh, Panagiotis Kassavetis, Melissa M. Cortez, Guillaume Lamotte

Erschienen in: Clinical Autonomic Research | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the effect of levodopa on postural blood pressure changes in individuals with Parkinson disease (PD) with (PD+OH) and without neurogenic OH (PD−OH).

Methods

We performed a prospective randomized crossover study with autonomic testing performed ON and OFF levodopa. The primary outcome was the change in systolic blood pressure (SBP) from supine to 70° tilt at 3 min (ΔSBP-3’). Secondary outcomes included indices of baroreflex function and blood pressure and heart rate during tilt.

Results

We enrolled 40 individuals with PD (21 PD+OH, 19 PD−OH), mean age (SD) 73.2 years (7.9), 13 women (32.5%)). There was no difference in age, sex, disease duration, and severity between PD+OH and PD−OH. Mean difference in ΔSBP-3’ ON versus OFF levodopa in the whole study population was − 3.20 mmHg [− 7.36 to 0.96] (p = 0.14). Mean difference in ΔSBP-3’ was − 2.14 mmHg [− 7.55 to 3.28] (p = 0.45) in PD+OH and − 5.14 mmHg [− 11.63 to 1.35] (p = 0.14) in PD−OH. Mean difference in ΔSBP ON versus OFF levodopa was greater at 7 and 10 min (− 7.52 mmHg [− 11.89 to − 3.15], p = 0.002, and − 7.82 mmHg [− 14.02 to − 1.67], p = 0.02 respectively). Levodopa was associated with lower absolute values of blood pressure in both PD+OH and PD−OH and cardiovascular noradrenergic baroreflex impairment.

Conclusion

Levodopa decreases blood pressure in both PD with and without autonomic failure, but it does not cause a greater fall in blood pressure from supine to standing at 3 min. Levodopa-induced baroreflex sympathetic noradrenergic impairment may contribute to lower blood pressure. Lower standing blood pressure with levodopa may increase the risks of fall and syncope.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795–808CrossRefPubMed Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795–808CrossRefPubMed
2.
Zurück zum Zitat Noack C, Schroeder C, Heusser K, Lipp A (2014) Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord 20(8):815–818CrossRefPubMed Noack C, Schroeder C, Heusser K, Lipp A (2014) Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord 20(8):815–818CrossRefPubMed
3.
Zurück zum Zitat McDonald C, Pearce M, Kerr SR, Newton J (2017) A prospective study of the association between orthostatic hypotension and falls: definition matters. Age Ageing 46(3):439–445PubMed McDonald C, Pearce M, Kerr SR, Newton J (2017) A prospective study of the association between orthostatic hypotension and falls: definition matters. Age Ageing 46(3):439–445PubMed
5.
Zurück zum Zitat Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729CrossRefPubMedPubMedCentral Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hiorth YH, Pedersen KF, Dalen I, Tysnes OB, Alves G (2019) Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology 93(16):e1526–e1534CrossRefPubMed Hiorth YH, Pedersen KF, Dalen I, Tysnes OB, Alves G (2019) Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology 93(16):e1526–e1534CrossRefPubMed
7.
Zurück zum Zitat Nimmons D, Bhanu C, Orlu M, Schrag A, Walters K (2022) Orthostatic hypotension and antiparkinsonian drugs: a systematic review and meta-analysis. J Geriatr Psychiatry Neurol 35(5):639–654CrossRefPubMed Nimmons D, Bhanu C, Orlu M, Schrag A, Walters K (2022) Orthostatic hypotension and antiparkinsonian drugs: a systematic review and meta-analysis. J Geriatr Psychiatry Neurol 35(5):639–654CrossRefPubMed
8.
Zurück zum Zitat Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A et al (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46(6):1333–1339CrossRefPubMed Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A et al (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46(6):1333–1339CrossRefPubMed
9.
Zurück zum Zitat Jost WH, Altmann C, Fiesel T, Becht B, Ringwald S, Hoppe T (2020) Influence of levodopa on orthostatic hypotension in Parkinson’s disease. Neurol Neurochir Pol 54(2):200–203PubMed Jost WH, Altmann C, Fiesel T, Becht B, Ringwald S, Hoppe T (2020) Influence of levodopa on orthostatic hypotension in Parkinson’s disease. Neurol Neurochir Pol 54(2):200–203PubMed
10.
Zurück zum Zitat Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM et al (2012) Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 18(5):501–505CrossRefPubMed Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM et al (2012) Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 18(5):501–505CrossRefPubMed
11.
Zurück zum Zitat Worth D, Harvey J, Brown J, Lee M (1988) The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man. Eur J Clin Pharmacol 35(2):137–141CrossRefPubMed Worth D, Harvey J, Brown J, Lee M (1988) The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man. Eur J Clin Pharmacol 35(2):137–141CrossRefPubMed
12.
Zurück zum Zitat Yue JL, Goshima Y, Miyamae T, Misu Y (1993) Evidence for L-dopa relevant to modulation of sympathetic activity in the rostral ventrolateral medulla of rats. Brain Res 629(2):310–314CrossRefPubMed Yue JL, Goshima Y, Miyamae T, Misu Y (1993) Evidence for L-dopa relevant to modulation of sympathetic activity in the rostral ventrolateral medulla of rats. Brain Res 629(2):310–314CrossRefPubMed
13.
Zurück zum Zitat Reid JL, Calne DB, George CF, Vakil SD (1972) The action of L(-)-dopa on baroreflexes in parkinsonism. Clin Sci 43(6):851–859CrossRefPubMed Reid JL, Calne DB, George CF, Vakil SD (1972) The action of L(-)-dopa on baroreflexes in parkinsonism. Clin Sci 43(6):851–859CrossRefPubMed
14.
Zurück zum Zitat Kaufmann H, Norcliffe-Kaufmann L, Palma JA (2020) Baroreflex dysfunction. N Engl J Med 382(2):163–178CrossRefPubMed Kaufmann H, Norcliffe-Kaufmann L, Palma JA (2020) Baroreflex dysfunction. N Engl J Med 382(2):163–178CrossRefPubMed
15.
Zurück zum Zitat Cheshire WP, Freeman R, Gibbons CH, Cortelli P, Wenning GK, Hilz MJ et al (2021) Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol 132(2):666–682CrossRefPubMed Cheshire WP, Freeman R, Gibbons CH, Cortelli P, Wenning GK, Hilz MJ et al (2021) Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol 132(2):666–682CrossRefPubMed
16.
Zurück zum Zitat Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRefPubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRefPubMed
17.
Zurück zum Zitat Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S et al (2017) The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 264(8):1567–1582CrossRefPubMedPubMedCentral Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S et al (2017) The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 264(8):1567–1582CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170CrossRefPubMed
19.
Zurück zum Zitat Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W (2012) COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc 87(12):1196–1201CrossRefPubMedPubMedCentral Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W (2012) COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc 87(12):1196–1201CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P et al (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 28(4):355–362CrossRefPubMedPubMedCentral Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P et al (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 28(4):355–362CrossRefPubMedPubMedCentral
21.
22.
Zurück zum Zitat Pickering TG, Sleight P (1969) Quantitative index of baroreflex activity in normal and hypertensive subjects using Valsalva’s manoeuvre. Br Heart J 31(3):392PubMed Pickering TG, Sleight P (1969) Quantitative index of baroreflex activity in normal and hypertensive subjects using Valsalva’s manoeuvre. Br Heart J 31(3):392PubMed
23.
Zurück zum Zitat Schrezenmaier C, Singer W, Swift NM, Sletten D, Tanabe J, Low PA (2007) Adrenergic and vagal baroreflex sensitivity in autonomic failure. Arch Neurol 64(3):381–386CrossRefPubMed Schrezenmaier C, Singer W, Swift NM, Sletten D, Tanabe J, Low PA (2007) Adrenergic and vagal baroreflex sensitivity in autonomic failure. Arch Neurol 64(3):381–386CrossRefPubMed
24.
Zurück zum Zitat Bouhaddi M, Vuillier F, Fortrat JO, Cappelle S, Henriet MT, Rumbach L et al (2004) Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci 116(1–2):30–38CrossRefPubMed Bouhaddi M, Vuillier F, Fortrat JO, Cappelle S, Henriet MT, Rumbach L et al (2004) Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci 116(1–2):30–38CrossRefPubMed
26.
Zurück zum Zitat Liu Z, Su D, Zhou J, Wang X, Wang Z, Yang Y et al (2023) Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson’s disease: results of acute levodopa challenge test. Parkinsonism Relat Disord 115:105860CrossRefPubMed Liu Z, Su D, Zhou J, Wang X, Wang Z, Yang Y et al (2023) Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson’s disease: results of acute levodopa challenge test. Parkinsonism Relat Disord 115:105860CrossRefPubMed
27.
28.
Zurück zum Zitat Torabi P, Ricci F, Hamrefors V, Sutton R, Fedorowski A (2020) Classical and delayed orthostatic hypotension in patients with unexplained syncope and severe orthostatic intolerance. Front Cardiovasc Med 7:21CrossRefPubMedPubMedCentral Torabi P, Ricci F, Hamrefors V, Sutton R, Fedorowski A (2020) Classical and delayed orthostatic hypotension in patients with unexplained syncope and severe orthostatic intolerance. Front Cardiovasc Med 7:21CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Li K, Haase R, Rüdiger H, Reimann M, Reichmann H, Wolz M et al (2017) Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease. Sci Rep 7(1):7012CrossRefPubMedPubMedCentralADS Li K, Haase R, Rüdiger H, Reimann M, Reichmann H, Wolz M et al (2017) Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease. Sci Rep 7(1):7012CrossRefPubMedPubMedCentralADS
30.
Zurück zum Zitat Durrieu G, Senard JM, Rascol O, Tran MA, Lataste X, Rascol A et al (1990) Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208–243). Neurology 40(4):707–709CrossRefPubMed Durrieu G, Senard JM, Rascol O, Tran MA, Lataste X, Rascol A et al (1990) Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208–243). Neurology 40(4):707–709CrossRefPubMed
31.
Zurück zum Zitat Mannelli M, Ianni L, Lazzeri C, Castellani W, Pupilli C, La Villa G et al (1999) In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension 34(3):398–402CrossRefPubMed Mannelli M, Ianni L, Lazzeri C, Castellani W, Pupilli C, La Villa G et al (1999) In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension 34(3):398–402CrossRefPubMed
32.
Zurück zum Zitat Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2(11):669–676CrossRefPubMed Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2(11):669–676CrossRefPubMed
33.
Zurück zum Zitat Newman DG, Callister R (1999) The non-invasive assessment of stroke volume and cardiac output by impedance cardiography: a review. Aviat Space Environ Med 70(8):780–789PubMed Newman DG, Callister R (1999) The non-invasive assessment of stroke volume and cardiac output by impedance cardiography: a review. Aviat Space Environ Med 70(8):780–789PubMed
Metadaten
Titel
Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study
verfasst von
Timi Earl
Amani Jridi
Perla C. Thulin
Meghan Zorn
Kathleen E. McKee
Kristin Mitrovich
Paolo Moretti
Jumana Alshaikh
Panagiotis Kassavetis
Melissa M. Cortez
Guillaume Lamotte
Publikationsdatum
02.03.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 1/2024
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-024-01024-5

Weitere Artikel der Ausgabe 1/2024

Clinical Autonomic Research 1/2024 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.